EP2709447A4 - Compositions, methods & systems for respiratory delivery of two or more active agents - Google Patents

Compositions, methods & systems for respiratory delivery of two or more active agents

Info

Publication number
EP2709447A4
EP2709447A4 EP11865780.8A EP11865780A EP2709447A4 EP 2709447 A4 EP2709447 A4 EP 2709447A4 EP 11865780 A EP11865780 A EP 11865780A EP 2709447 A4 EP2709447 A4 EP 2709447A4
Authority
EP
European Patent Office
Prior art keywords
compositions
systems
methods
active agents
respiratory delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11865780.8A
Other languages
German (de)
French (fr)
Other versions
EP2709447A1 (en
Inventor
Reinhard Vehring
Michael Steven Hartman
David Lechuga-Ballesteros
Adrian Edward Smith
Vidya B Joshi
Sarvajna Kumar Dwivedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pearl Therapeutics Inc
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of EP2709447A1 publication Critical patent/EP2709447A1/en
Publication of EP2709447A4 publication Critical patent/EP2709447A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
    • A61L9/02—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air by heating or combustion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11865780.8A 2011-05-17 2011-05-17 Compositions, methods & systems for respiratory delivery of two or more active agents Withdrawn EP2709447A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/036868 WO2012158166A1 (en) 2011-05-17 2011-05-17 Compositions, methods & systems for respiratory delivery of two or more active agents

Publications (2)

Publication Number Publication Date
EP2709447A1 EP2709447A1 (en) 2014-03-26
EP2709447A4 true EP2709447A4 (en) 2014-10-22

Family

ID=47177229

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11865780.8A Withdrawn EP2709447A4 (en) 2011-05-17 2011-05-17 Compositions, methods & systems for respiratory delivery of two or more active agents

Country Status (13)

Country Link
EP (1) EP2709447A4 (en)
JP (1) JP2014518871A (en)
KR (1) KR20140032404A (en)
CN (1) CN103687483A (en)
AU (1) AU2011368334A1 (en)
BR (1) BR112013029507A2 (en)
CA (1) CA2835927A1 (en)
EA (1) EA201490991A1 (en)
IL (1) IL229260A0 (en)
MX (1) MX2013013440A (en)
RU (1) RU2013155903A (en)
SG (1) SG194896A1 (en)
WO (1) WO2012158166A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20110132357A1 (en) 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
CN104955448A (en) 2013-01-31 2015-09-30 普罗索尼克斯有限公司 Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP2999460A1 (en) * 2013-05-22 2016-03-30 Pearl Therapeutics, Inc. Compositions, methods&systems for respiratory delivery of three or more active agents
HUE039359T2 (en) * 2013-12-30 2018-12-28 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
MX368835B (en) * 2013-12-30 2019-10-18 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
US10532041B2 (en) 2014-09-09 2020-01-14 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
EP3288541B1 (en) * 2015-05-01 2020-09-02 Board of Regents, The University of Texas System Multidrug brittle matrix compositions
CN105125542A (en) * 2015-08-23 2015-12-09 杭州紫金医药科技有限公司 Medicine composition with tiotropium bromide and formoterol, application of medicine composition and preparation
CN106880636A (en) * 2015-12-15 2017-06-23 天津金耀集团有限公司 A kind of ciclesonide folk prescription and compound dry powder inhalation composition
CN106880637B (en) * 2015-12-15 2021-01-29 天津金耀集团有限公司 Ciclesonide formoterol and tiotropium bromide compound dry powder inhalant composition
CN106943350A (en) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 Aerosol and preparation method containing muscarinic receptor antagonist and β 2 receptor agonist
US20210393598A1 (en) * 2018-11-12 2021-12-23 Kindeva Drug Delivery L.P. Umeclidinium and vilanterol formulation and inhaler
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
CN111467498A (en) * 2020-05-14 2020-07-31 王兆霖 Pharmaceutical composition preparation
WO2022148418A1 (en) * 2021-01-08 2022-07-14 江苏恒瑞医药股份有限公司 Pharmaceutical composition capable of being delivered by metered dose inhaler
CA3226153A1 (en) * 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175549A1 (en) * 2004-02-06 2005-08-11 Sofotec Gmbh & Co. Kg Novel combination of anticholinergic and ss mimetics for the treatment of respiratory diseases
WO2010138862A2 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100572171B1 (en) * 1997-09-29 2006-04-19 넥타르 테라퓨틱스 Stabilizing Agents for Dosage Inhalers
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
SE527190C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175549A1 (en) * 2004-02-06 2005-08-11 Sofotec Gmbh & Co. Kg Novel combination of anticholinergic and ss mimetics for the treatment of respiratory diseases
WO2010138862A2 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
WO2010138884A2 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012158166A1 *

Also Published As

Publication number Publication date
AU2011368334A1 (en) 2013-11-21
CA2835927A1 (en) 2012-11-22
KR20140032404A (en) 2014-03-14
EP2709447A1 (en) 2014-03-26
EA201490991A1 (en) 2014-09-30
MX2013013440A (en) 2014-06-05
JP2014518871A (en) 2014-08-07
WO2012158166A1 (en) 2012-11-22
RU2013155903A (en) 2015-06-27
BR112013029507A2 (en) 2019-09-24
CN103687483A (en) 2014-03-26
SG194896A1 (en) 2013-12-30
IL229260A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
IL229260A0 (en) Compositions,methods & systems for respiratory delivery of two or more active agents
IL216468A0 (en) Compositions, methods & systems for respiratory respiratory delivery of two or more active agents
ZA201903184B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
HK1221654A1 (en) Compositions, methods & systems for respiratory delivery of three or more active agents
PL2768937T3 (en) Formulations, their use as or for the manufacture of dishwashing agents and their manufacture
EP2787071A4 (en) Equol concentration increasing agent containing psicose as active ingredient
HK1208188A1 (en) Formulations for the delivery of active ingredients
HK1179534A1 (en) Coated preparation containing azosemide as active ingredient
EP2692348A4 (en) Antitumor agent containing carbon dioxide as active ingredient
HUE047420T2 (en) Dosage form for the controlled release of active ingredients
HK1203068A1 (en) Systems and methods for generating germicidal compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20140924

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/08 20060101ALI20140918BHEP

Ipc: A61K 9/72 20060101ALI20140918BHEP

Ipc: A61K 31/167 20060101AFI20140918BHEP

Ipc: A61P 11/00 20060101ALI20140918BHEP

Ipc: A61K 31/40 20060101ALI20140918BHEP

Ipc: A61K 9/10 20060101ALI20140918BHEP

Ipc: A61K 9/12 20060101ALI20140918BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1195450

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1195450

Country of ref document: HK